Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations

Cytokine and Growth Factor Reviews

Volumn 26, Issue 4, 2015, Pages 425-449

  Gallo, Leandro H ^a   Nelson, Katelyn N ^a   Meyer, April N ^a   Donoghue, Daniel J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Development; Fibroblast Growth Factor Receptor; Myeloproliferative syndrome; Rhabdomyosarcoma; Translocation

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; ANTINEOPLASTIC AGENT; AZD 4547; AZD 8010; BCR FGFR1 FUSION PROTEIN; CEP110 FGFR1 FUSION PROTEIN; CYSTEINE; DOVITINIB; ERLOTINIB; FGFR1 FUSION PROTEIN; FGFR1OP FGFR1 FUSION PROTEIN; FGFR2 AHCYL1 FUSION PROTEIN; FGFR2 FUSION PROTEIN; FGFR3 BAIAP2L1 FUSION PROTEIN; FGFR3 TACC3 FUSION PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GEFITINIB; HYBRID PROTEIN; IMATINIB; PAZOPANIB; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; TIF1 FGFR1 FUSION PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZNF198 FGFR1 FUSION PROTEIN;

ACROCEPHALOSYNDACTYLY; ACUTE MYELOBLASTIC LEUKEMIA; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CARCINOGENESIS; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CERVICAL SQUAMOUS CELL CARCINOMA; CHROMOSOME REARRANGEMENT; CHRONIC MYELOID LEUKEMIA; DIMERIZATION; DOWN REGULATION; DRUG EFFICACY; DRUG PROTEIN BINDING; ENDOMETRIUM CARCINOMA; FGFR4 GENE; GAIN OF FUNCTION MUTATION; GALLBLADDER CANCER; GENE; GENE OVEREXPRESSION; GENE SEQUENCE; GENE TRANSLOCATION; GENOMICS; GERMLINE MUTATION; GLIOBLASTOMA; HUMAN; LOSS OF FUNCTION MUTATION; LUNG ADENOCARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOUTH SQUAMOUS CELL CARCINOMA; MULTIPLE MYELOMA; MUTATIONAL ANALYSIS; NONHUMAN; PILOCYTIC ASTROCYTOMA; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; RHABDOMYOSARCOMA; SHORT SURVEY; SIGNAL TRANSDUCTION; SOMATIC MUTATION; SPERMATOCYTIC SEMINOMA; SQUAMOUS CELL LUNG CARCINOMA; STOMACH CANCER; STOP CODON; THANATOPHORIC DWARFISM; UROTHELIAL CANCER; GENETICS; METABOLISM; MUTATION; NEOPLASM;

HUMANS; MUTATION; NEOPLASMS; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSLOCATION, GENETIC;

EID: 84938286765     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2015.03.003     Document Type: Short Survey

References (209)

1. Robertson S.C., Tynan J., Donoghue D.J. RTK mutations and human syndromes: when good receptors turn bad. Trends Genet 2000, 16:368.
2. Wilkie A.O. Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev 2005, 16:187-203.
3. Dailey L., Ambrosetti D., Mansukhani A., Basilico C. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 2005, 16:233-247.
4. Eswarakumar V.P., Lax I., Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005, 16:139-149.
5. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010, 10:116-129.
6. Ahmad I., Iwata T., Leung H.Y. Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta 2012, 1823:850-860.
7. Robertson S.C., Meyer A.N., Hart K.C., Galvin B.D., Webster M.K., Donoghue D.J. Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain. Proc Natl Acad Sci U S A 1998, 95:4567-4572.
8. Padmanabhan V., Hegde A.M., Rai K. Crouzon's syndrome: a review of literature and case report. Contemp Clin Dent 2011, 2:211-214.
9. Goriely A., Hansen R.M., Taylor I.B., Olesen I.A., Jacobsen G.K., McGowan S.J., et al. Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. Nat Genet 2009, 41:1247-1252.
10. Reardon W., Winter R.M., Rutland P., Pulleyn L.J., Jones B.M., Malcolm S. Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nat Genet 1994, 8:98-103.
11. Galvin B.D., Hart K.C., Meyer A.N., Webster M.K., Donoghue D.J. Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR)2 and FGFR2/Neu chimeras. Proc Natl Acad Sci U S A 1996, 93:7894-7899.
12. Reintjes N., Li Y., Becker A., Rohmann E., Schmutzler R., Wollnik B. Activating somatic FGFR2 mutations in breast cancer. PLoS ONE 2013, 8:e60264.
13. Liao R.G., Jung J., Tchaicha J., Wilkerson M.D., Sivachenko A., Beauchamp E.M., et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res 2013, 73:5195-5205.
14. d'Avis P.Y., Robertson S.C., Meyer A.N., Bardwell W.M., Webster M.K., Donoghue D.J. Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. Cell Growth Differ 1998, 9:71-78.
15. Muenke M., Schell U., Hehr A., Robin N.H., Losken H.W., Schinzel A., et al. A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome. Nat Genet 1994, 8:269-274.
16. Ibrahimi O.A., Eliseenkova A.V., Plotnikov A.N., Yu K., Ornitz D.M., Mohammadi M. Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. Proc Natl Acad Sci U S A 2001, 98:7182-7187.
17. Nagata M., Nuckolls G.H., Wang X., Shum L., Seki Y., Kawase T., et al. The primary site of the acrocephalic feature in Apert Syndrome is a dwarf cranial base with accelerated chondrocytic differentiation due to aberrant activation of the FGFR2 signaling. Bone 2011, 48:847-856.
18. Webster M.K., Donoghue D.J. FGFR activation in skeletal disorders: too much of a good thing. Trends Genet 1997, 13:178-182.
19. Ahmed Z., Schuller A.C., Suhling K., Tregidgo C., Ladbury J.E. Extracellular point mutations in FGFR2 elicit unexpected changes in intracellular signalling. Biochem J 2008, 413:37-49.
20. Wilkie A.O., Slaney S.F., Oldridge M., Poole M.D., Ashworth G.J., Hockley A.D., et al. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat Genet 1995, 9:165-172.
21. Moloney D.M., Slaney S.F., Oldridge M., Wall S.A., Sahlin P., Stenman G., et al. Exclusive paternal origin of new mutations in Apert syndrome. Nat Genet 1996, 13:48-53.
22. Chen P., Zhang L., Weng T., Zhang S., Sun S., Chang M., et al. A Ser252Trp mutation in fibroblast growth factor receptor 2 (FGFR2) mimicking human Apert syndrome reveals an essential role for FGF signaling in the regulation of endochondral bone formation. PLOS ONE 2014, 9:e87311.
23. Dutt A., Salvesen H.B., Chen T.H., Ramos A.H., Onofrio R.C., Hatton C., et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A 2008, 105:8713-8717.
24. Bell C.A., Tynan J.A., Hart K.C., Meyer A.N., Robertson S.C., Donoghue D.J. Rotational coupling of the transmembrane and kinase domains of the Neu receptor tyrosine kinase. Mol Biol Cell 2000, 11:3589-3599.
25. Sarabipour S., Hristova K. FGFR3 unliganded dimer stabilization by the juxtamembrane domain. J Mol Biol 2015.
26. Byron S.A., Gartside M.G., Wellens C.L., Goodfellow P.J., Birrer M.J., Campbell I.G., et al. FGFR2 mutations are rare across histologic subtypes of ovarian cancer. Gynecol Oncol 2010, 117:125-129.
27. Wenger T.L., Bhoj E.J., Wetmore R.F., Mennuti M.T., Bartlet S.P., Mollen T.J., et al. Beare-Stevenson syndrome: two new patients, including a novel finding of tracheal cartilaginous sleeve. Am J Med Genet A 2015, 167:852-857.
28. Webster M.K., Donoghue D.J. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. Embo J 1996, 15:520-527.
29. Tavormina P.L., Shiang R., Thompson L.M., Zhu Y.Z., Wilkin D.J., Lachman R.S., et al. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet 1995, 9:321-328.
30. Shiang R., Thompson L.M., Zhu Y.Z., Church D.M., Fielder T.J., Bocian M., et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 1994, 78:335-342.
31. Rousseau F., Bonaventure J., Legeai-Mallet L., Pelet A., Rozet J.M., Maroteaux P., et al. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 1994, 371:252-254.
32. Pollock P.M., Gartside M.G., Dejeza L.C., Powell M.A., Mallon M.A., Davies H., et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007, 26:7158-7162.
33. Li Y., Mangasarian K., Mansukhani A., Basilico C. Activation of FGF receptors by mutations in the transmembrane domain. Oncogene 1997, 14:1397-1406.
34. Ruhe J.E., Streit S., Hart S., Wong C.H., Spech K., Knyazev P., et al. Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res 2007, 67:11368-11376.
35. Zhu X., Zheng L., Asa S.L., Ezzat S. Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer. Am J Pathol 2010, 177:2860-2869.
36. Bange J., Prechtl D., Cheburkin Y., Specht K., Harbeck N., Schmitt M., et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 2002, 62:840-847.
37. Thussbas C., Nahrig J., Streit S., Bange J., Kriner M., Kates R., et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 2006, 24:3747-3755.
38. Jezequel P., Campion L., Joalland M.P., Millour M., Dravet F., Classe J.M., et al. G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. Br J Cancer 2004, 90:189-193.
39. Wang J., Stockton D.W., Ittmann M. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 2004, 10:6169-6178.
40. Tateno T., Asa S.L., Zheng L., Mayr T., Ullrich A., Ezzat S. The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis. PLoS Genet 2011, 7:e1002400.
41. Webster M.K., D'Avis P.Y., Robertson S.C., Donoghue D.J. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol Cell Biol 1996, 16:4081-4087.
42. Manickam K., Donoghue D.J., Meyer A.N., Snyder P.J., Prior T.W. Suppression of severe achondroplasia with developmental delay and acanthosis nigricans by the p.Thr651Pro mutation. Am J Med Genet A 2014, 164A:243-250.
43. Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A., et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001, 97:729-736.
44. Naski M.C., Wang Q., Xu J., Ornitz D.M. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 1996, 13:233-237.
45. Bellus G.A., Bamshad M.J., Przylepa K.A., Dorst J., Lee R.R., Hurko O., et al. Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3. Am J Med Genet 1999, 85:53-65.
46. Lievens P.M., Mutinelli C., Baynes D., Liboi E. The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling. J Biol Chem 2004, 279:43254-43260.
47. Gibbs L., Legeai-Mallet L. FGFR3 intracellular mutations induce tyrosine phosphorylation in the Golgi and defective glycosylation. Biochim Biophys Acta 2007, 1773:502-512.
48. Meyer A.N., McAndrew C.W., Donoghue D.J. Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells. Cancer Res 2008, 68:7362-7370.
49. van Rhijn B.W., van der Kwast T.H., Liu L., Fleshner N.E., Bostrom P.J., Vis A.N., et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol 2012, 187:310-314.
50. van Rhijn B.W., Lurkin I., Radvanyi F., Kirkels W.J., van der Kwast T.H., Zwarthoff E.C. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001, 61:1265-1268.
51. Ahmad I., Singh L.B., Foth M., Morris C.A., Taketo M.M., Wu X.R., et al. K-Ras and beta-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder. Dis Model Mech 2011, 4:548-555.
52. Foth M., Ahmad I., van Rhijn B.W., van der Kwast T., Bergman A.M., King L., et al. Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice. J Pathol 2014, 233:148-158.
53. Juanpere N., Agell L., Lorenzo M., de Muga S., Lopez-Vilaro L., Murillo R., et al. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer. Hum Pathol 2012, 43:1573-1582.
54. Bellus G.A., McIntosh I., Smith E.A., Aylsworth A.S., Kaitila I., Horton W.A., et al. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat Genet 1995, 10:357-359.
55. Chen L.I., Webster M.K., Meyer A.N., Donoghue D.J. Transmembrane domain sequence requirements for activation of the p185c-neu receptor tyrosine kinase. J Cell Biol 1997, 137:619-631.
56. Chen H., Ma J., Li W., Eliseenkova A.V., Xu C., Neubert T.A., et al. A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol Cell 2007, 27:717-730.
57. Locascio L.E., Donoghue D.J. KIDs rule: regulatory phosphorylation of RTKs. Trends Biochem Sci 2013, 38:75-84.
58. Xiang L., Li J., Jiang W., Shen X., Yang W., Wu X., et al. Comprehensive analysis of targetable oncogenic mutations in Chinese cervical cancers. Oncotarget 2015, 6:4968-4975.
59. Wang J.K., Goldfarb M. Amino acid residues which distinguish the mitogenic potentials of two FGF receptors. Oncogene 1997, 14:1767-1778.
60. Jones D.T., Hutter B., Jager N., Korshuno A., Kool M., Warnatz H.J., et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 2013, 45:927-932.
61. Jones D.T., Kocialkowski S., Liu L., Pearson D.M., Backlund L.M., Ichimura K., et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008, 68:8673-8677.
62. Jones D.T., Kocialkowski S., Liu L., Pearson D.M., Ichimura K., Collins V.P. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 2009, 28:2119-2123.
63. Jones D.T., Gronych J., Lichter P., Witt O., Pfister S.M. MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci 2012, 69:1799-1811.
64. Gessi M., Moneim Y.A., Hammes J., Goschzik T., Scholz M., Denkhaus D., et al. FGFR1 mutations in Rosette-forming glioneuronal tumors of the fourth ventricle. J Neuropathol Exp Neurol 2014, 73:580-584.
65. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
66. Xia S.J., Pressey J.G., Barr F.G. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther 2002, 1:97-104.
67. Ray A., Huh W.W. Current state-of-the-art systemic therapy for pediatric soft tissue sarcomas. Curr Oncol Rep 2012, 14:311-319.
68. Taylor J.G.T., Cheuk A.T., Tsang P.S., Chung J.Y., Song Y.K., Desai K., et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 2009, 119:3395-3407.
69. Li S.Q., Cheuk A.T., Shern J.F., Song Y.K., Hurd L., Liao H., et al. Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534). PLoS ONE 2013, 8:e76551.
70. Seiwert T.Y., Zuo Z., Keck M.K., Khattri A., Pedamallu C.S., Stricker T.P., et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res 2015, 21:632-641.
71. Shern J.F., Chen L., Chmielecki J., Wei J.S., Patidar R., Rosenberg M., et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov 2014, 4:216-231.
72. Lesca E., Lammens A., Huber R., Augustin M. Structural analysis of the human fibroblast growth factor receptor 4 kinase. J Mol Biol 2014, 426:3744-3756.
73. Cao L., Yu Y., Bilke S., Walker R.L., Mayeenuddin L.H., Azorsa D.O., et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res 2010, 70:6497-6508.
74. Crose L.E., Etheridge K.T., Chen C., Belyea B., Talbot L.J., Bentley R.C., et al. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Clin Cancer Res 2012, 18:3780-3790.
75. Gartside M.G., Chen H., Ibrahimi O.A., Byron S.A., Curtis A.V., Wellens C.L., et al. Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol Cancer Res 2009, 7:41-54.
76. Lew E.D., Bae J.H., Rohmann E., Wollnik B., Schlessinger J. Structural basis for reduced FGFR2 activity in LADD syndrome: Implications for FGFR autoinhibition and activation. Proc Natl Acad Sci U S A 2007, 104:19802-19807.
77. Rohmann E., Brunner H.G., Kayserili H., Uyguner O., Nurnberg G., Lew E.D., et al. Mutations in different components of FGF signaling in LADD syndrome. Nat Genet 2006, 38:414-417.
78. Rousseau F., Saugier P., Le Merrer M., Munnich A., Delezoide A.L., Maroteaux P., et al. Stop codon FGFR3 mutations in thanatophoric dwarfism type 1. Nat Genet 1995, 10:11-12.
79. Rousseau F., el Ghouzzi V., Delezoide A.L., Legeai-Mallet L., Le Merrer M., Munnich A., et al. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1). Hum Mol Genet 1996, 5:509-512.
80. Xue Y., Sun A., Mekikian P.B., Martin J., Rimoin D.L., Lachman R.S., et al. FGFR3 mutation frequency in 324 cases from the International Skeletal Dysplasia Registry. Mol Genet Genomic Med 2014, 2:497-503.
81. Sierra J.R., Cepero V., Giordano S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer 2010, 9:75.
82. Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.K., et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008, 105:2070-2075.
83. Kosaka T., Yatabe Y., Endoh H., Yoshida K., Hida T., Tsuboi M., et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006, 12:5764-5769.
84. Branford S., Rudzki Z., Walsh S., Grigg A., Arthur C., Taylor K., et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002, 99:3472-3475.
85. Mauro M.J. Defining and managing imatinib resistance. Hematol Am Soc Hematol Educ Program 2006, 219-225.
86. Blencke S., Zech B., Engkvist O., Greff Z., Orfi L., Horvath Z., et al. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem Biol 2004, 11:691-701.
87. Renhowe P.A., Pecchi S., Shafer C.M., Machajewski T.D., Jazan E.M., Taylor C., et al. Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors. J Med Chem 2009, 52:278-292.
88. Trudel S., Li Z.H., Wei E., Wiesmann M., Chang H., Chen C., et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005, 105:2941-2948.
89. Lopes de Menezes D.E., Peng J., Garrett E.N., Louie S.G., Lee S.H., Wiesmann M., et al. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clin Cancer Res 2005, 11:5281-5291.
90. Xin X., Abrams T.J., Hollenbach P.W., Rendahl K.G., Tang Y., Oei Y.A., et al. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res 2006, 12:4908-4915.
91. Byron S.A., Chen H., Wortmann A., Loch D., Gartside M.G., Dehkhoda F., et al. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Neoplasia 2013, 15:975-988.
92. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
93. Greulich H., Pollock P.M. Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol Med 2011, 17:283-292.
94. Chell V., Balmanno K., Little A.S., Wilson M., Andrews S., Blockley L., et al. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene 2013, 32:3059-3070.
95. Jackson C.C., Medeiros L.J., Miranda R.N. 8p11 myeloproliferative syndrome: a review. Hum Pathol 2010, 41:461-476.
96. Wu Y.M., Su F., Kalyana-Sundaram S., Khazanov N., Ateeq B., Cao X., et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013, 3:636-647.
97. Wang R., Wang L., Li Y., Hu H., Shen L., Shen X., et al. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Clin Cancer Res 2014, 20:4107-4114.
98. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525.
99. Maeda T., Yagasaki F., Ishikawa M., Takahashi N., Bessho M. Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML. Blood 2005, 105:2115-2123.
100. Parker B.C., Engels M., Annala M., Zhang W. Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours. J Pathol 2014, 232:4-15.
101. Guo G., Sun X., Chen C., Wu S., Huang P., Li Z., et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 2013, 45:1459-1463.
102. Williams S.V., Hurst C.D., Knowles M.A. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 2013, 22:795-803.
103. Kim Y., Hammerman P.S., Kim J., Yoon J.A., Lee Y., Sun J.M., et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol 2014, 32:121-128.
104. Majewski I.J., Mittempergher L., Davidson N.M., Bosma A., Willems S.M., Horlings H.M., et al. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol 2013, 230:270-276.
105. Parker B.C., Annala M.J., Cogdell D.E., Granberg K.J., Sun Y., Ji P., et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest 2013, 123:855-865.
106. Singh D., Chan J.M., Zoppoli P., Niola F., Sullivan R., Castano A., et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012, 337:1231-1235.
107. Javle M., Rashid A., Churi C., Kar S., Zuo M., Eterovic A.K., et al. Molecular characterization of gallbladder cancer using somatic mutation profiling. Hum Pathol 2014, 45:701-708.
108. Di Stefano A.L., Fucci A., Frattini V., Labussiere M., Mokhtari K., Zoppoli P., et al. Detection, characterization and inhibition of FGFR-TACC fusions in IDH wild type glioma. Clin Cancer Res 2015, epub 2199.2014.
109. Arai Y., Totoki Y., Hosoda F., Shirota T., Hama N., Nakamura H., et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 2014, 59:1427-1434.
110. Ross J.S., Wang K., Gay L., Al-Rohil R., Rand J.V., Jones D.M., et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist 2014, 19:235-242.
111. Borad M.J., Champion M.D., Egan J.B., Liang W.S., Fonseca R., Bryce A.H., et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet 2014, 10:e1004135.
112. Witkowski W.A., Hardy J.A. L2' loop is critical for caspase-7 active site formation. Protein Sci 2009, 18:1459-1468.
113. Matikas A., Tzannou I., Oikonomopoulou D., Bakiri M. A case of acute myelogenous leukaemia characterised by the BCR-FGFR1 translocation. BMJ Case Rep 2013, 2013.
114. Wasag B., Lierman E., Meeus P., Cools J., Vandenberghe P. The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11). Haematologica 2011, 96:922-926.
115. Onozawa M., Ohmura K., Ibata M., Iwasaki J., Okada K., Kasahara I., et al. The 8p11 myeloproliferative syndrome owing to rare FGFR1OP2-FGFR1 fusion. Eur J Haematol 2011, 86:347-349.
116. Seo J.S., Ju Y.S., Lee W.C., Shin J.Y., Lee J.K., Bleazard T., et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 2012, 22:2109-2119.
117. Martignetti J.A., Camacho-Vanegas O., Priedigkeit N., Camacho C., Pereir E., Lin L., et al. Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA. Neoplasia 2014, 16:97-103.
118. Sia D., Losic B., Moeini A., Cabellos L., Hao K., Revill K., et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun 2015, 6:6087.
119. Li F., Zhai Y.P., Tang Y.M., Wang L.P., Wan P.J. Identification of a novel partner gene, TPR, fused to FGFR1 in 8p11 myeloproliferative syndrome. Genes Chromosomes Cancer 2012, 51:890-897.
120. Xiao S., McCarthy J.G., Aster J.C., Fletcher J.A. ZNF198-FGFR1 transforming activity depends on a novel proline-rich ZNF198 oligomerization domain. Blood 2000, 96:699-704.
121. Kiyoi H., Naoe T. FLT3 in human hematologic malignancies. Leuk Lymphoma 2002, 43:1541-1547.
122. Medves S., Demoulin J.B. Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies. J Cell Mol Med 2012, 16:237-248.
123. Guasch G., Mack G.J., Popovici C., Dastugue N., Birnbaum D., Rattner J.B., et al. FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33). Blood 2000, 95:1788-1796.
124. Gergely F., Karlsson C., Still I., Cowell J., Kilmartin J., Raff J.W. The TACC domain identifies a family of centrosomal proteins that can interact with microtubules. Proc Natl Acad Sci U S A 2000, 97:14352-14357.
125. Browman D.T., Resek M.E., Zajchowski L.D., Robbins S.M. Erlin-1 and erlin-2 are novel members of the prohibitin family of proteins that define lipid-raft-like domains of the ER. J Cell Sci 2006, 119:3149-3160.
126. Guasch G., Ollendorff V., Borg J.P., Birnbaum D., Pebusque M.J. 8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways. Mol Cell Biol 2001, 21:8129-8142.
127. Chen J., Williams I.R., Lee B.H., Duclos N., Huntly B.J., Donoghue D.J., et al. Constitutively activated FGFR3 mutants signal through PLC{gamma}-dependent and -independent pathways for hematopoietic transformation. Blood 2005, 106:328-337.
128. Gervais C., Dano L., Perrusson N., Helias C., Jeandidier E., Galois A.C., et al. A translocation t(2;8)(q12;p11) fuses FGFR1 to a novel partner gene, RANBP2/NUP358, in a myeloproliferative/myelodysplastic neoplasm. Leukemia 2013, 27:1186-1188.
129. Hiwatari M., Taki T., Taketani T., Taniwaki M., Sugita K., Okuya M., et al. Fusion of an AF4-related gene, LAF4, to MLL in childhood acute lymphoblastic leukemia with t(2;11)(q11;q23). Oncogene 2003, 22:2851-2855.
130. Demiroglu A., Steer E.J., Heath C., Taylor K., Bentley M., Allen S.L., et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 2001, 98:3778-3783.
131. Acquaviva J., He S., Zhang C., Jimenez J.P., Nagai M., Sang J., et al. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism. Mol Cancer Res 2014, 12:1042-1054.
132. Chase A., Grand F.H., Cross N.C. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood 2007, 110:3729-3734.
133. de Brito L.R., Batey M.A., Zhao Y., Squires M.S., Maitland H., Leung H.Y., et al. Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma. Leuk Res 2011, 35:1233-1240.
134. Bacher U., Haferlach T., Schnittger S., Weiss T., Burkhard O., Bechtel B., et al. Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia. Cancer Genet Cytogenet 2010, 200:170-174.
135. Cerny J., Yu H., Miron P.M. Novel FGFR3 rearrangement t(4;22)(p16;q11.2) in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma. Ann Hematol 2013, 92:1433-1435.
136. Liu J., Guzman M.A., Pezanowski D., Patel D., Hauptman J., Keisling M., et al. FOXO1-FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcoma. Mod Pathol 2011, 24:1327-1335.
137. Lee J.C., Jeng Y.M., Su S.Y., Wu C.T., Tsai K.S., Lee C.H., et al. Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour. J Pathol 2015, 235:539-545.
138. Nakamura Y., Ito Y., Wakimoto N., Kakegawa E., Uchida Y., Bessho M. A novel fusion of SQSTM1 and FGFR1 in a patient with acute myelomonocytic leukemia with t(5;8)(q35;p11) translocation. Blood Cancer J 2014, 4:e265.
139. Duckworth C.B., Zhang L., Li S. Systemic mastocytosis with associated myeloproliferative neoplasm with t(8;19)(p12;q13.1) and abnormality of FGFR1: report of a unique case. Int J Clin Exp Pathol 2014, 7:801-807.
140. Ma K., Qiu L., Mrasek K., Zhang J., Liehr T., Quintana L.G., et al. Common fragile sites: genomic hotspots of DNA damage and carcinogenesis. Int J Mol Sci 2012, 13:11974-11999.
141. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
142. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337.
143. Bardelli A., Parsons D.W., Silliman N., Ptak J., Szabo S., Saha S., et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003, 300:949.
144. Dulak A.M., Stojanov P., Peng S., Lawrence M.S., Fox C., Stewart C., et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 2013, 45:478-486.
145. Rand V., Huang J., Stockwell T., Ferriera S., Buzko O., Levy S., et al. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci U S A 2005, 102:14344-14349.
146. Stransky N., Egloff A.M., Tward A.D., Kostic A.D., Cibulskis K., Sivachenko A., et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333:1157-1160.
147. Davies H., Hunter C., Smith R., Stephens P., Greenman C., Bignell G., et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005, 65:7591-7595.
148. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
149. Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L., Borg A., et al. Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RARbeta signaling. Mol Cancer Res 2013, 11:1166-1178.
150. Stephens P.J., Davies H.R., Mitani Y., Van Loo P., Shlien A., Tarpey P.S., et al. Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest 2013, 123:2965-2968.
151. Hansen R.M., Goriely A., Wall S.A., Roberts I.S., Wilkie A.O. Fibroblast growth factor receptor 2, gain-of-function mutations, and tumourigenesis: investigating a potential link. J Pathol 2005, 207:27-31.
152. Byron S.A., Gartside M., Powell M.A., Wellens C.L., Gao F., Mutch D.G., et al. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS ONE 2012, 7:e30801.
153. Jang J.H., Shin K.H., Park J.G. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 2001, 61:3541-3543.
154. Tchaicha J.H., Akbay E.A., Altabef A., Mikse O.R., Kikuchi E., Rhee K., et al. Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC. Cancer Res 2014, 74:4676-4684.
155. Jones D.T., Jager N., Kool M., Zichner T., Hutter B., Sultan M., et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012, 488:100-105.
156. Pickering C.R., Zhang J., Yoo S.Y., Bengtsson L., Moorthy S., Neskey D.M., et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov 2013, 3:770-781.
157. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014, 507:315-322.
158. Kompier L.C., Lurkin I., van der Aa M.N., van Rhijn B.W., van der Kwast T.H., Zwarthoff E.C. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS ONE 2010, 5:e13821.
159. Vallot C., Stransky N., Bernard-Pierrot I., Herault A., Zucman-Rossi J., Chapeaublanc E., et al. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J Natl Cancer Inst 2011, 103:47-60.
160. Billerey C., Chopin D., Aubriot-Lorton M.H., Ricol D., Gil Diez de Medina S., Van Rhijn B., et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001, 158:1955-1959.
161. Van Rhijn B.W., Van Tilborg A.A., Lurkin I., Bonaventure J., De Vries A., Thiery J.P., et al. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet 2002, 10:819-824.
162. Cappellen D., De Oliveira C., Ricol D., de Medina S., Bourdin J., Sastre-Garau X., et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999, 23:18-20.
163. Lopez-Knowles E., Hernandez S., Malats N., Kogevinas M., Lloreta J., Carrato A., et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 2006, 66:7401-7404.
164. Hernandez S., Lopez-Knowles E., Lloreta J., Kogevinas M., Amoro A., Tardon A., et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006, 24:3664-3671.
165. Lindgren D., Liedberg F., Andersson A., Chebil G., Gudjonsson S., Borg A., et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 2006, 25:2685-2696.
166. Sibley K., Cuthbert-Heavens D., Knowles M.A. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene 2001, 20:686-691.
167. Cazier J.B., Rao S.R., McLean C.M., Walker A.K., Wright B.J., Jaeger E.E., et al. Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden. Nat Commun 2014, 5:3756.
168. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
169. Frattini V., Trifonov V., Chan J.M., Castano A., Lia M., Abate F., et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 2013, 45:1141-1149.
170. Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups. Nat Commun 2013, 4:2873.
171. Gaykalova D.A., Mambo E., Choudhary A., Houghton J., Buddavarapu K., Sanford T., et al. Novel insight into mutational landscape of head and neck squamous cell carcinoma. PLOS ONE 2014, 9:e93102.
172. Shinmura K., Kato H., Matsuura S., Inoue Y., Igarashi H., Nagura K., et al. A novel somatic FGFR3 mutation in primary lung cancer. Oncol Rep 2014, 31:1219-1224.
173. Shukuya T., Serizawa M., Watanabe M., Akamatsu H., Abe M., Imai H., et al. Identification of actionable mutations in malignant pleural mesothelioma. Lung Cancer 2014, 86:35-40.
174. Claudio J.O., Zhan F., Zhuang L., Khaja R., Zhu Y.X., Sivananthan K., et al. Expression and mutation status of candidate kinases in multiple myeloma. Leukemia 2007, 21:1124-1127.
175. Onwuazor O.N., Wen X.Y., Wang D.Y., Zhuang L., Masih-Khan E., Claudio J., et al. Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. Blood 2003, 102:772-773.
176. Soverini S., Terragna C., Testoni N., Ruggeri D., Tosi P., Zamagni E., et al. Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis. Haematologica 2002, 87:1036-1040.
177. Intini D., Baldini L., Fabris S., Lombardi L., Ciceri G., Maiolo A.T., et al. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). Br J Haematol 2001, 114:362-364.
178. Ronchetti D., Greco A., Compasso S., Colombo G., Dell'Era P., Otsuki T., et al. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 2001, 20:3553-3562.
179. Fracchiolla N.S., Luminari S., Baldini L., Lombardi L., Maiolo A.T., Neri A. FGFR3 gene mutations associated with human skeletal disorders occur rarely in multiple myeloma. Blood 1998, 92:2987-2989.
180. Intini D., Baldini L., Lombardi L., Neri A. A novel mutation involving the carboxy terminal region of the FGFR3 gene in a multiple myeloma patient with t(4;14). Leukemia 2002, 16:1201-1202.
181. Zhang Y., Hiraishi Y., Wang H., Sumi K.S., Hayashido Y., Toratan S., et al. Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas. Int J Cancer 2005, 117:166-168.
182. Hafner C., van Oers J.M., Hartmann A., Landthaler M., Stoehr R., Blaszyk H., et al. High frequency of FGFR3 mutations in adenoid seborrheic keratoses. J Invest Dermatol 2006, 126:2404-2407.
183. Marks J.L., McLellan M.D., Zakowski M.F., Lash A.E., Kasai Y., Broderick S., et al. Mutational analysis of EGFR and related signaling pathway genes in lung Adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS ONE 2007, 2:e426.
184. Bellus G.A., Gaudenz K., Zackai E.H., Clarke L.A., Szabo J., Francomano C.A., et al. Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes. Nat Genet 1996, 14:174-176.
185. Tavormina P.L., Bellus G.A., Webster M.K., Bamshad M.J., Fraley A.E., McIntosh I., et al. A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am J Hum Genet 1999, 64:722-731.
186. Meyers G.A., Orlow S.J., Munro I.R., Przylepa K.A., Jabs E.W. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet 1995, 11:462-464.
187. Bellus G.A., Spector E.B., Speiser P.W., Weaver C.A., Garber A.T., Bryke C.R., et al. Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. Am J Hum Genet 2000, 67:1411-1421.
188. Kan S.H., Elanko N., Johnson D., Cornejo-Roldan L., Cook J., Reich E.W., et al. Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis. Am J Hum Genet 2002, 70:472-486.
189. Liu C., Cui Y., Luan J., Zhou X., Han J. The molecular and cellular basis of Apert syndrome. Intractable Rare Dis Res 2013, 2:115-122.
190. Goos J.A., van den Ouweland A.M., Swagemakers S.M., Verkerk A.J., Hoogeboom A.J., van Veelen M.L., et al. A novel mutation in FGFR2. Am J Med Genet A 2015, 167A:123-127.
191. Nakanishi Y., Akiyama N., Tsukaguchi T., Fujii T., Satoh Y., Ishii N., et al. Mechanism of oncogenic signal activation by the novel fusion kinase FGFR3-BAIAP2L1. Mol Cancer Ther 2015, 14:704-712.
192. Bao Z.S., Chen H.M., Yang M.Y., Zhang C.B., Yu K., Ye W.L., et al. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome Res 2014, 24:1765-1773.
193. Yuan L., Liu Z.H., Lin Z.R., Xu L.H., Zhong Q., Zeng M.S. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma. Cancer Biol Ther 2014, 15:1613-1621.
194. Capelletti M., Dodge M.E., Ercan D., Hammerman P.S., Park S.I., Kim J., et al. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. Clin Cancer Res 2014, 20:6551-6558.
195. Yagasaki F., Wakao D., Yokoyama Y., Uchida Y., Murohashi I., Kayano H., et al. Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. Cancer Res 2001, 61:8371-8374.
196. Kim S.Y., Oh B., She C.J., Kim H.K., Jeon Y.K., Shin M.G., et al. 8p11 Myeloproliferative syndrome with BCR-FGFR1 rearrangement presenting with T-lymphoblastic lymphoma and bone marrow stromal cell proliferation: a case report and review of the literature. Leuk Res 2011, 35:e30-e34.
197. Murati A., Arnoulet C., Lafage-Pochitaloff M., Adelaide J., Derre M., Slama B., et al. Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion. Int J Oncol 2005, 26:1485-1492.
198. Baldazzi C., Iacobucci I., Luatti S., Ottaviani E., Marzocchi G., Paolini S., et al. B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. Leuk Res 2010, 34:e282-e285.
199. Dolan M., Cioc A., Cross N.C., Neglia J.P., Tolar J. Favorable outcome of allogeneic hematopoietic cell transplantation for 8p11 myeloproliferative syndrome associated with BCR-FGFR1 gene fusion. Pediatr Blood Cancer 2012, 59:194-196.
200. Morishige S., Oku E., Takata Y., Kimura Y., Arakawa F., Seki R., et al. A case of 8p11 myeloproliferative syndrome with BCR-FGFR1 gene fusion presenting with trilineage acute leukemia/lymphoma, successfully treated by cord blood transplantation. Acta Haematol 2013, 129:83-89.
201. Shimanuki M., Sonoki T., Hosoi H., Watanuki J., Murata S., Mushino T., et al. Acute leukemia showing t(8;22)(p11;q11), myelodysplasia, CD13/CD33/CD19 expression and immunoglobulin heavy chain gene rearrangement. Acta Haematol 2013, 129:238-242.
202. Lee S.G., Park T.S., Lee S.T., Lee K.A., Song J., Kim J., et al. Rare translocations involving chromosome band 8p11 in myeloid neoplasms. Cancer Genet Cytogenet 2008, 186:127-129.
203. Wakim J.J., Tirado C.A., Chen W., Collins R. t(8;22)/BCR-FGFR1 myeloproliferative disorder presenting as B-acute lymphoblastic leukemia: report of a case treated with sorafenib and review of the literature. Leuk Res 2011, 35:e151-e153.
204. Sarahx O.J., Anthony A.O., Titilope A.A., Alani S.A. The 8p12 myeloproliferative syndrome. Niger Med J 2014, 55:176-179.
205. Gu T.L., Goss V.L., Reeves C., Popova L., Nardone J., Macneill J., et al. Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. Blood 2006, 108:4202-4204.
206. Guasch G., Popovici C., Mugneret F., Chaffanet M., Pontarotti P., Birnbaum D., et al. Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3). Blood 2003, 101:286-288.
207. Kim S.Y., Kim J.E., Park S., Kim H.K. Molecular identification of a TPR-FGFR1 fusion transcript in an adult with myeloproliferative neoplasm, T-lymphoblastic lymphoma, and a t(1;8)(q25;p11.2). Cancer Genet 2014, 207:258-262.
208. Kim W.S., Park S.G., Park G., Jang S.J., Moon D.S., Kang S.H. 8p11 myeloproliferative syndrome with t(1;8)(q25;p11.2): a case report and review of the literature. Acta Haematol 2015, 133:101-105.
209. Chen X., Zhang Y., Li Y., Lei P., Zhai Y., Liu L. Biphenotypic hematologic malignancy: a case report of the 8p11 myeloproliferative syndrome in a child. J Pediatr Hematol Oncol 2010, 32:501-503.